Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02669043 · ClinicalTrials.gov registry record · NA
Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects
A NA study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT02669043: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT02669043 is a NA study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02669043, a NA study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
Anxious depression is a particularly difficult-to-treat subtype of depression. Patients with anxious depression do not respond as well to currently available antidepressant medications. Nevertheless, in previous studies, low dose IV ketamine, which rapidly decreases symptoms of depression within hours in many patients with "treatment-resistant" depression, has been associated with superior efficacy in those individuals with anxious compared with non-anxious depression. In order to understand this unique effect more fully, the current protocol is aimed at further delineating biomarkers of ketamine's effects among individuals with treatment-resistant anxious depression compared to those with nonanxious depression.
Primary Outcome
Continuous score of depression symptoms. The higher the score, the more severe the depression. HAMD scores range from 0 to 81.
Interventions
- DRUG Ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-02 |
| Phase | NA |
Why NCT02669043 stopped before completion
NCT02669043 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Ketamine is the first listed.
NCT02669043 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02669043 about?
NCT02669043 is a clinical study titled "Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects". Anxious depression is a particularly difficult-to-treat subtype of depression. Patients with anxious depression do not respond as well to currently available antidepressant medications. Nevertheless, in previous studies, low dose IV ketamine, which rapidly decreases symptoms of depression within hou...
What is the current status of trial NCT02669043?
This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2016-07. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02669043?
The interventions under investigation include: Ketamine (DRUG).
Who is sponsoring clinical trial NCT02669043?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02669043's enrollment target sits among peer trials
8 1976th of 2000 higher than 19 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia